A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

Lupin Ltd has introduced Ipratropium Bromide nasal spray in the US, available in 0.03% and 0.06% strengths. These sprays, ...

Ipratropium bromide nasal solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with ...

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

Lupin launches Ipratropium Bromide Nasal Solution in the US market; eyes expanding complex generics pipeline to over 200 ...

MomMed, a trusted maternal and family wellness brand, today announced a strategic partnership with nasal care innovator ...

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Mumbai: Global pharma major Lupin Limited has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in ...

Lupin launches Ipratropium Bromide nasal spray in US, bioequivalent to Atrovent. The product addresses rhinitis and targets a $63 million market opportunity.

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Lupin announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are ...